Insulet Corporation
HQ US25% share
Maker of the Omnipod tubeless patch insulin pump — the dominant patch pump.
manufactured · input
Insulin Delivery Devices (Pen Injectors & Insulin Pumps)
The devices that administer insulin subcutaneously: reusable/disposable insulin pen injectors and durable/patch insulin pumps with their infusion-set consumables. In developed markets pen injectors are the dominant insulin delivery format and pumps are standard of care for intensive therapy; vials + syringes remain a lower-cost fallback. Device makers include Novo Nordisk and Eli Lilly (captive pens), Ypsomed (mylife YpsoPump + CDMO pens), Insulet, Tandem, and Medtronic (pumps).
0
Source countries
4
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on insulin delivery devices (pen injectors & insulin pumps) somewhere upstream in their supply chain.
Who makes it
Supplier companies
4 companies produce insulin delivery devices (pen injectors & insulin pumps).
Eli Lilly and Company(LLY)
HQ US
Second-largest insulin manufacturer; invented the first commercial insulin (1923). Uses Saccharomyces cerevisiae (yeast) fermentation exclusively. Markets Humalog (lispro), Basaglar (glargine), and Lyumjev. Also dominant in GLP-1 market (Mounjaro/Zepbound). FY2024 revenue ~$45B.
Novo Nordisk(NVO)
HQ DK
World's largest insulin manufacturer. Controls ~33.7% of global diabetes care market; ~45% of human insulin. Operates the world's largest insulin production facility in Kalundborg, Denmark (produces ~50% of global insulin supply). Dominant in GLP-1 drugs (Ozempic/Wegovy); FY2024 revenue DKK 232B. Uses both E. coli and yeast fermentation.
Ypsomed(YPSN.SW)
HQ CH
Swiss self-injection device maker; YpsoMate autoinjector platform. Carved out its diabetes unit to focus on GLP-1 self-injectors and signed a long-term autoinjector supply deal with Novo Nordisk.